SETDB1 and neoplasm: The study discovered that SETDB1 negatively regulates the expression of miR-22 by downregulating FOSB. Moreover, SETDB1 was found to downregulate PD-L1 expression by targeting BATF3. When SETDB1 was silenced, T cell-mediated cytotoxicity against tumor cells increased, leading to hindered tumor growth and reduced infiltration of immune cells (p values < 0.05) [123].